Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It treats colorectal cancer, including metastatic disease, in adult patients.

GNH USA supplies Irinotecan Accord as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan is a topoisomerase I inhibitor used in the management of colorectal cancer and related disease stages.

- Colorectal cancer: administered as part of combination chemotherapy to reduce tumor size and improve survival. - Metastatic colorectal cancer: used to control disease spread and extend progression‑free survival. - Unresectable colorectal cancer: employed to shrink tumors and enable possible surgical intervention.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes during infusion. - Diarrhea: can be acute or delayed. - Neutropenia: reduced white blood cell count. - Alopecia: hair thinning or loss. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils. - Severe diarrhea/colitis: may lead to dehydration. - Allergic reactions: rash, itching, or anaphylaxis. - Hepatic toxicity: elevated liver enzymes. - Pulmonary toxicity: interstitial lung disease. - Electrolyte disturbances: severe imbalances requiring monitoring.

Before initiating therapy, several safety considerations should be addressed. - Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: baseline and periodic LFTs are recommended. - Evaluate renal function: adjust dosing if impairment is present. - Avoid in patients with known hypersensitivity to irinotecan or its excipients. - Use effective contraception: advise contraception during treatment and for a defined period after. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce irinotecan exposure. - Concurrent myelosuppressive agents: increase risk of severe neutropenia. - UGT1A1 inhibitors (e.g., atazanavir): can raise SN‑38 levels and toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR for altered effect. - Antiemetics (e.g., ondansetron): watch for QT prolongation. - Other antineoplastic drugs: dose adjustments may be required. - Proton pump inhibitors: may affect gastrointestinal absorption.